Related Experiment Video
Updated: Jul 4, 2025
10:00
Supramaximal Intensity Hypoxic Exercise and Vascular Function Assessment in Mice
Published on: March 15, 2019
8.4K
Hypoxia Attenuates Pressure Overload-Induced Heart Failure
Natali Froese1, Malgorzata Szaroszyk1, Paolo Galuppo1
1Department of Cardiology and Angiology Hannover Medical School Hannover Germany.
Journal of the American Heart Association
|January 31, 2024
Summary
Alveolar hypoxia protects against heart failure by activating protective pathways. These mechanisms may also aid recovery in patients with advanced heart failure receiving mechanical circulatory support.
Area of Science:
- Cardiovascular Research
- Physiology
- Molecular Biology
Background:
- Alveolar hypoxia demonstrates cardioprotective effects in cardiovascular and ischemic heart disease, but mechanisms remain unclear.
- Left ventricular pressure overload (LVPO) induces heart failure, necessitating investigation into protective strategies.
- Understanding hypoxia's role is crucial for developing novel therapeutic interventions for heart failure.
Purpose of the Study:
- To test the hypothesis that hypoxia is cardioprotective in LVPO-induced heart failure.
- To investigate if similar mechanisms promote cardiac recovery in heart failure patients undergoing mechanical unloading.
- To identify hypoxia-mediated cardioprotective mechanisms and potential therapeutic targets.
Main Methods:
- Established a novel murine model of chronic alveolar hypoxia and LVPO (HxTAC).
- Utilized RNA sequencing to analyze gene expression changes in the HxTAC model.
- Analyzed patient samples from those with advanced heart failure and left ventricular assist device support.
Main Results:
- The HxTAC model showed resistance to cardiac hypertrophy and heart failure development.
- Key protective mechanisms included increased HIF-1α activation, attenuated pathological remodeling genes, and preserved metabolic gene expression.
- Hypoxia attenuated detrimental changes in Tbx5 and Hsd11b1 mRNA expression, observed in LVPO under normoxia, and mirrored in patient recovery.
Conclusions:
- Hypoxia effectively attenuates LVPO-induced heart failure in a novel murine model.
- Identified cardioprotective pathways in the HxTAC model may contribute to myocardial recovery post-mechanical circulatory support.
- The HxTAC model serves as a valuable tool for discovering hypoxia-mediated therapeutic targets for heart failure.
Keywords:
cardiac hypertrophycardiac remodelinghypoxialeft ventricular assist devicepressure overloadMore Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:21Acute Respiratory Failure-II
236
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
236
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
216
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
216
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381